iStockPhoto / Getty Images
Lisa Schaffer can reel off a long list of the labels that people who live with obesity routinely receive.
“We’re just lazy. We can’t take care of ourselves. We’re disengaged with our own health. We can’t stop ourselves,” says Schaffer, executive director at Obesity Canada.
These are not playground taunts: The idea that obesity is a lifestyle choice pervades the healthcare system, starting in doctors’ offices.
Schaffer vividly recalls diligently keeping a food diary, taking it into her primary care physician and being all but accused of lying. She says her health professional did not recognize that weight is determined by a multitude of factors – genetics, environment, biology and more – not just ‘eat less, move more.’
“When we call obesity a ‘lifestyle problem,’ it assumes that everything is in my control,” says Schaffer, who blames the continued influence of diet culture for this attitude, which attaches a morality to body size. “We need to understand obesity for what it is, because when we don’t, we don’t see people for who they are.”
It may also be keeping Canadians from accessing the treatment they seek.
“It’s a collision course of people who truly need it having to fight for it and prove that they’re ‘worthy’ of it,” Schaffer says. “It’s really disheartening, because we know that if we treat obesity earlier in life, we can potentially remove over 200 downstream impacts of other conditions. Treatment is also prevention.”
In Quebec, for example, provincial healthcare does not currently cover treatments for obesity. In 2024, the government began a two-year pilot project to determine whether or not to cover Ozempic — which is currently only covered provincially for diabetes — for obesity. Alberta, on the other hand, became the first province to recognize obesity as a disease in March 2025.
“They’re very deeply invested in getting this right because they see the impact of what this is doing to the healthcare system overall,” says Schaffer, who points to an Obesity Canada report from 2024, which found that obesity costs Canada $27.6-billion annually.
Taline Sarkissian, vice president, medical affairs at Lilly, a medicine company working to advance the treatment of obesity, says understanding that obesity is a complex medical condition is key to ensuring people get the treatment they need.
“It’s not just about the physical appearance. It’s about all the other conditions that are driven by obesity. That’s where the evolution has happened,” Sarkissian says. “It’s still evolving, but we’re definitely seeing progress.”
It’s why the company is taking a “portfolio” approach to its obesity treatment options, recognizing the complexity of this medical condition.
“We don’t think there’s just one solution for every person living with obesity,” Sarkissian says. “We’re studying a diversity of treatment approaches, including injectables and oral therapies. It’s pushing us to look beyond standard of care.”
It’s also doing its part to make it easier for Canadians who need these medications to access them.
“We’re seeing progress with education and policies beginning to catch up with the science,” Sarkissian says. “At Lilly, we’re working across the whole healthcare ecosystem – with government, with public and private drug plans, employers, clinicians – to help address some of those barriers.”
The goal, she adds, is for “stakeholders to take obesity as seriously as any other chronic disease.”
For Schaffer, this shift presents a “massive opportunity” for Canada.
“Canada has so much to be proud of,” she says, listing the country’s rich history in obesity treatment leadership. “If we can help with better implementation and structure, we can show many people around the world how to do this.”
To learn more about Lilly Canada’s innovation history, and to hear about Canada’s role in life sciences research and innovation, visit lilly.ca.
Advertising feature produced by The Globe and Mail Content Studio with Lilly Canada. The Globe’s editorial department was not involved.














